Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Calibr-Skaggs Institute for Innovative Medicines
Calibr-Skaggs Advances CLF065, a Regenerative GLP-2 Therapy, into Two Phase 2 IBD Studies
Today 9:00 EDT
From
Calibr-Skaggs Institute for Innovative Medicines
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.